|
Real-time
Boerse Muenchen
05:14:06 2026-09-16 EDT
|
5-day change | 1st Jan Change | ||
| 0.3390 EUR | -24.67% |
|
+24.31% | +51.26% |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
| 09-11 | Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 33.73M | - | - | - | ||
| 355B | |||||
| 65.7B | |||||
| 12.06B | |||||
| 7.56B | |||||
| 4.49B |
- Stock Market
- Stocks
- ALCOX Stock
- NXOA Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
